Drug Administration Schedule

Publication Title: 
Bulletin of the World Health Organization

OBJECTIVE: To evaluate the therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine, and the sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated Plasmodium falciparum malaria in young children in Cameroon.

Author(s): 
Basco, Leonardo K.
Same-Ekobo, Albert
Ngane, Vincent Foumane
Ndounga, Mathieu
Metoh, Theresia
Ringwald, Pascal
Soula, Georges
Publication Title: 
The American Journal of Tropical Medicine and Hygiene

The combination of artesunate and mefloquine is currently one of the most effective treatments against multidrug-resistant Plasmodium falciparum malaria. To improve patient compliance to such a combination, the two agents have been combined in a prepacked single blister. Patients were instructed to simultaneously co-administer the drugs once a day for three days. In the present randomized, double-blind, parallel group, comparative, single center study in Thailand, this concept was investigated in 204 adults and children with acute, uncomplicated P. falciparum malaria.

Author(s): 
Krudsood, S.
Looareesuwan, S.
Silachamroon, U.
Chalermrut, K.
Pittrow, D.
Cambon, N.
Mueller, E. A.
Publication Title: 
Revista Da Sociedade Brasileira De Medicina Tropical

with the objective of evaluating shortened therapeutic outlines effective in vivax malaria treatment, we accomplished an open, prospective study allocating 234 patients with vivax malaria distributed at random into eight therapeutic groups. Six groups used oral arthemisin as blood esquizonticide at different doses for one day and the other two groups received chloroquine in a single dose. The primaquine was used as a hypnozoiticide in all groups. They received a daily dose of 30mg in the course of five or seven days in all groups.

Author(s): 
da Silva, Rita do Socorro Uchôa
Pinto, Ana Yecê das Neves
Calvosa, Vanja Suely Pachiano
de Souza, José Maria
Publication Title: 
The American Journal of Tropical Medicine and Hygiene

We studied prospectively 801 Thai patients admitted to the Bangkok Hospital for Tropical Diseases with acute, symptomatic Plasmodium vivax malaria to determine the optimum duration of treatment with oral artesunate and the safety, tolerability, and effectiveness of a high dose of primaquine in prevention of relapse.

Author(s): 
Silachamroon, Udomsak
Krudsood, Srivicha
Treeprasertsuk, Sombat
Wilairatana, Polrat
Chalearmrult, Kobsiri
Mint, Hla Yin
Maneekan, Pannamas
White, Nicholas J.
Gourdeuk, Victor R.
Brittenham, Gary M.
Looareesuwan, Sornchai
Publication Title: 
The Journal of Infectious Diseases

Combination antimalarial therapy may delay the spread of drug resistance, but clinical data supporting this notion are limited. For 1 year, we studied Ugandan children who were treated for uncomplicated malaria with sulfadoxine-pyrimethamine (SP), SP + amodiaquine (AQ), or SP + artesunate (AS). We compared treatment responses and the prevalence of resistance-conferring mutations of new infections with those of recrudescent infections due to parasites that survived prior treatment.

Author(s): 
Dorsey, Grant
Vlahos, Jonathan
Kamya, Moses R.
Staedke, Sarah G.
Rosenthal, Philip J.
Publication Title: 
The American Journal of Tropical Medicine and Hygiene

To study the efficacy, tolerance, population pharmacokinetics and pharmacodynamics of artesunate followed by mefloquine at various intervals, 360 patients with Plasmodium falciparum malaria received 4 mg/kg of artesunate and thereafter 15 mg/kg of mefloquine simultaneously (group A), after 8 hours (after group B), and after 24 hours (group C). Three dosages were completed with placebo. Follow-up was 28 days. All patients recovered rapidly except one case of failure within the first 24 hours. Mefloquine pharmacokinetics was similar in the three regimens.

Author(s): 
Hung, Le Q.
de Vries, Peter J.
Binh, Tran Q.
Giao, Phan T.
Nam, Nguyen V.
Holman, R.
Kager, Piet A.
Publication Title: 
The American Journal of Tropical Medicine and Hygiene

Measuring baseline levels of adherence and identifying risk factors for non-adherence are important steps before the introduction of new antimalarials. In Mbarara in southwestern Uganda, we assessed adherence to artemether-lumefantrine (Coartem) in its latest World Health Organization blister formulation. Patients with uncomplicated Plasmodium falciparum malaria were prescribed artemether-lumefantrine and received an explanation of how to take the following five doses at home. A tablet count was made and a questionnaire was completed during a home visit.

Author(s): 
Fogg, Carole
Bajunirwe, Francis
Piola, Patrice
Biraro, Samuel
Checchi, Francesco
Kiguli, James
Namiiro, Proscovia
Musabe, Joy
Kyomugisha, Agnes
Guthmann, Jean-Paul
Publication Title: 
The American Journal of Tropical Medicine and Hygiene

The efficacy of amodiaquine (AQ) and sulfadoxine-pyrimethamine (SP) was assessed in 310 symptomatic children from western Kenya with uncomplicated Plasmodium falciparum malaria. A non-blinded, randomized, 14-day study was performed and parasitologic criteria were used. Of 310 patients included, 238 (77%) completed the study: 120 received AQ and 118 received SP.

Author(s): 
Vreugdenhil, C. J.
Scheper, F. Y.
Hoogstraatte, S. R.
Smolders, M.
Gikunda, S.
Cobelens, F. G.
Kager, P. A.
Publication Title: 
Tropical medicine & international health: TM & IH

In the Maheba Refugee Settlement, in the clinics supported by Medecins Sans Frontieres, all children aged up to 5 years with a confirmed diagnosis of uncomplicated falciparum malaria are treated with the combination of sulfadoxine/pyrimethamine (SP) and artesunate (AS). We compared the treatment's efficacy and effectiveness. Patients were randomized in order to receive the treatment supervised (efficacy) or unsupervised (effectiveness). Therapeutic response was determined after 28 days of follow up.

Author(s): 
Depoortere, Evelyn
Guthmann, Jean-Paul
Pressé, Jacinthe
Sipilanyambe, Naawa
Nkandu, Esther
Balkan, Suna
de Pécoulas, Philippe Eldin
Legros, Dominique
Publication Title: 
PLoS medicine

BACKGROUND: Between 1995 and 2000, KwaZulu-Natal province, South Africa, experienced a marked increase in Plasmodium falciparum malaria, fuelled by pyrethroid and sulfadoxine-pyrimethamine resistance. In response, vector control was strengthened and artemether-lumefantrine (AL) was deployed in the first Ministry of Health artemisinin-based combination treatment policy in Africa. In South Africa, effective vector and parasite control had historically ensured low-intensity malaria transmission.

Author(s): 
Barnes, Karen I.
Dürrheim, David N.
Little, Francesca
Jackson, Amanda
Mehta, Ushma
Allen, Elizabeth
Dlamini, Sicelo S.
Tsoka, Joyce
Bredenkamp, Barry
Mthembu, D. Jotham
White, Nicholas J.
Sharp, Brian L.

Pages

Subscribe to RSS - Drug Administration Schedule